Enterprise Europe Network

License agreements are sought for a novel medical technology which repairs upper respiratory tract tissues and sterilizes biological cells.

Country of origin:
External Id: 
Last update
Expiration date


Partner keyword: 
Medical Research
Medical Technology / Biomedical Engineering
Virus, Virology/Antibiotics/Bacteriology
Therapeutic services
Electromedical and medical equipment
Research and experimental development on biotechnology


The novel biomedical technology developed by a Turkish engineering company offers license agreements for the treatment of upper respiratory tract associated diseases including Coronaviruses and Acute Respiratory Syndromes. The technology uses endoscopic procedures to biologically sterilize the upper tract and repair damaged tissues within the trachea through cold plasma therapy. License agreements are sought.



Turkish engineering corporation conducting R&D studies on biomedical appliances -predominantly on plasma technologies- developed a novel biomedical technology to cure upper respiratory tract associated diseases including Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS). The company based at one of the reputable science parks in Ankara/Turkey seeks business partners for license agreements.
The therapy provides rapid sterilization of the surface with the indirect plasma effect on the tissue and repairs the damaged upper respiratory tract with plasma radicals and reactive atoms. The technology covers a natural and organic process with zero side effects for the treatment of currently known diseases including COVID-19, MERS, SARS and any upper respiratory tract associated viral diseases that may emerge in the future.
40-60mm probe has an oral indirect cold plasma reactor and camera integrated on it. Briefly, it is orally intubated into the trachea, microorganisms on the tissue are inhibited, and the damaged tissues are treated with indirect plasma impulse to the fragment up to the tracheal bifurcation. Plasma formation is provided by gas that enables necessary ionization for radicals and electrons for the upper tract and lungs. Reactive oxygen species formed through plasma ionization inhibit microorganisms in the fragment. It also provides ionization of the active substances of medication to accelerate the treatment or it can be used in severe cases with the Dielectric Barrier Discharge reactor (DBD) and enables rapid penetration of the drug to tissues and cells with plasma impulse.
What is key to this process:
1. Microorganisms' not being resistant to Reactive Oxygen Species (ROS) and Reactive Oxygen and Nitrogen Species (RONS) formed in the plasma impulse area,
2. Acceleration of the process by activating the regeneration of tissues and cells through biological effects with plasma.
3. The device has a system for instant imaging of tissues and plasma with the help of a micro camera on its probe.
Patent applications for the technology is made for the treatment and license agreements are sought. Potential partners are preferred to have knowledge and experience in the medical sector, preferably in plasma technologies.

Advantages & innovations

Cooperation plus value: 
• Introduced technology is slightly different from similar appliances because the design, and operation principle is totally different from its use for plasma processes. • Device includes the cold indirect plasma process, directly contacts tissues, cells, and microorganisms with the help of the plasma impulse in the fragment up to the tracheal bifurcation within the trachea. • The probe has been scaled to a microreactor size to be used with endoscopic techniques. • The technology also a has imaging system. It shows up to a 45% positive effect on ionization efficiency and energy consumption.

Stage of development

Cooperation stage dev stage: 
Available for demonstration

Partner sought

Cooperation area: 
Potential partners are expected to have some knowledge and experience in the medical sector, preferably in plasma technologies.

Type and size

Cooperation task: 
SME 11-50,R&D Institution,SME <10,SME 51-250